The traditional means of measuring quality in health care focuses on processes, rather than disease outcomes, so providers often are forced to check off boxes without really focusing on the health status of the patients they are treating. These measures aren’t based on the care patients actually received, and they don’t truly capture what every provider can do to prevent bad outcomes.
With support from RWJF, the National Committee for Quality Assurance (NCQA) is evaluating a promising way of measuring quality that focuses on improving health outcomes for patients with heart disease and diabetes. Called the Global Cardiovascular Risk Score (GCVR), this new approach is being co-developed by NCQA and Archimedes, Inc., another RWJF grantee. The GCVR score is seen as a next-generation quality improvement tool that will provide much more accurate and effective incentives to providers for preventing disease.
The GCVR score has the potential to transform how providers, patients and payers view the measurement of health care quality because it will assess how well providers engage in prevention strategies to keep high-risk patients as healthy as possible.
The GVCR will help purchasers of health care benefits get the best value for their health care dollar. “This particular measure is a very different approach and therefore it could be a game-changer,” says Helen Darling, President of the National Business Group on Health.
With support from Pioneer, NCQA and Archimedes, Inc., will develop and test the Global Cardiovascular Risk (GCVR) score over the coming months.
On April 9, NCQA announced a new approach to measuring quality that aims to reduce patients’ risk of heart disease and stroke. David Eddy of Archimedes, Inc., discusses what this means for providers in a post for The Health Care Blog.
people die each year from heart disease. Find out how @rwjf is working to prevent this.
Stroke under 65
Nearly 1 in 3 people in the U.S. who suffer a stroke are under the age of 65
The GCVR is a game-changer for measuring quality, promoting prevention, and assessing the impact of health care decisions on patient outcomes,” says Risa Lavizzo-Mourey, president and CEO of the Robert Wood Johnson Foundation. “Measuring quality in this way could have major implications for improving patient care and lowering costs because this is focused on preventing adverse health outcomes, not just on care processes or goals, which has been the standard until now.”
This is an example of a truly disruptive innovation that could really make quality measurement a much more meaningful exercise. It focuses providers on preventing disease and averting bad health outcomes and tells us what works.”